A Trial on the Efficacy, Safety and Immunogenicity of Live-Attenuated Influenza Vaccine (LAIV)

PHASE3CompletedINTERVENTIONAL
Enrollment

9,000

Participants

Timeline

Start Date

November 30, 2016

Primary Completion Date

August 31, 2017

Conditions
Influenza
Interventions
BIOLOGICAL

Live-Attenuated influenza Vaccine(LAIV)

BIOLOGICAL

Placebo

Trial Locations (3)

310051

Zhejiang Provincial Center for Disease Control and Prevention, Hangzhou

511430

Guangdong Provincial Institute of Biological Products and Materia Media, Guangzhou

050021

Hebei Provincial Center for Disease Control and Prevention, Shijiazhuang

All Listed Sponsors
collaborator

Simoon Record Pharma Information Consulting Co., Ltd.

INDUSTRY

collaborator

National Institutes for Food and Drug Control, China

OTHER

collaborator

Baoding Municipal Center for Disease Control and Prevention, Hebei, P.R.China

UNKNOWN

collaborator

Zhejiang Provincial Center for Disease Control and Prevention

OTHER_GOV

collaborator

Maoming Municipal Center for Disease Control and Prevention, Guangdong, P.R.China

UNKNOWN

collaborator

Department of Medical Statistics, Fourth Military Medical University

UNKNOWN

lead

Changchun BCHT Biotechnology Co.

INDUSTRY

NCT02964065 - A Trial on the Efficacy, Safety and Immunogenicity of Live-Attenuated Influenza Vaccine (LAIV) | Biotech Hunter | Biotech Hunter